Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
作者信息
Pfender Nikolai, Jelcic Ilijas, Linnebank Michael, Schwarz Urs, Martin Roland
机构信息
From the University Hospital Zurich, Switzerland.
出版信息
Neurology. 2015 Jun 9;84(23):2377-8. doi: 10.1212/WNL.0000000000001659. Epub 2015 May 8.
Abstract
摘要
相似文献
1
Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
Neurology. 2015 Jun 9;84(23):2377-8. doi: 10.1212/WNL.0000000000001659. Epub 2015 May 8.
2
Fingolimod for multiple sclerosis.
Drug Ther Bull. 2012 Feb;50(2):18-20. doi: 10.1136/dtb.2012.02.0086.
3
Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
Mult Scler. 2013 Aug;19(9):1244-5. doi: 10.1177/1352458512472750. Epub 2013 Jan 15.
4
Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.
JAMA Ophthalmol. 2013 Jun;131(6):802-4. doi: 10.1001/jamaophthalmol.2013.2465.
5
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28.
6
Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis.
Mult Scler. 2014 Nov;20(13):1792-3. doi: 10.1177/1352458514531844. Epub 2014 May 27.
7
Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
Neurology. 2009 Mar 17;72(11):1022-4. doi: 10.1212/01.wnl.0000344567.51394.e3.
8
Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.
Neurol Sci. 2014 Sep;35(9):1485-6. doi: 10.1007/s10072-014-1800-y. Epub 2014 Apr 23.
9
Safety and efficacy of reduced fingolimod dosage treatment.
J Neuroimmunol. 2015 Aug 15;285:13-5. doi: 10.1016/j.jneuroim.2015.05.012. Epub 2015 May 15.
10
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Neurology. 2013 Jul 9;81(2):174-81. doi: 10.1212/WNL.0b013e31829a3311. Epub 2013 May 22.
引用本文的文献
1
The Probable Infectious Origin of Multiple Sclerosis.
NeuroSci. 2023 Sep 7;4(3):211-234. doi: 10.3390/neurosci4030019. eCollection 2023 Sep.
2
Virus-Induced Epilepsy vs. Epilepsy Patients Acquiring Viral Infection: Unravelling the Complex Relationship for Precision Treatment.
Int J Mol Sci. 2024 Mar 27;25(7):3730. doi: 10.3390/ijms25073730.
3
Understanding the link between neurotropic viruses, BBB permeability, and MS pathogenesis.
J Neurovirol. 2024 Feb;30(1):22-38. doi: 10.1007/s13365-023-01190-8. Epub 2024 Jan 8.
4
Atypical molluscum contagiosum on multiple sclerosis patients treated with fingolimod: A case report.
Clin Case Rep. 2022 Oct 3;10(10):e6382. doi: 10.1002/ccr3.6382. eCollection 2022 Oct.
5
Cerebral Venous Thrombosis due to Cryptococcus in a Multiple Sclerosis Patient on Fingolimod.
Case Rep Neurol. 2022 Jun 24;14(2):286-290. doi: 10.1159/000524359. eCollection 2022 May-Aug.
6
Signaling sphingolipids are biomarkers for atopic dermatitis prone to disseminated viral infections.
J Allergy Clin Immunol. 2022 Sep;150(3):640-648. doi: 10.1016/j.jaci.2022.02.027. Epub 2022 Mar 15.
7
Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study.
Mult Scler J Exp Transl Clin. 2022 Jan 4;8(1):20552173211065731. doi: 10.1177/20552173211065731. eCollection 2022 Jan-Mar.
8
Dementia and cognitive impairment in adults as sequels of HSV-1-related encephalitis: a review.
Dement Neuropsychol. 2021 Apr-Jun;15(2):164-172. doi: 10.1590/1980-57642021dn15-020002.
9
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.
Caspian J Intern Med. 2021 Apr;12(3):263-274. doi: 10.22088/cjim.12.3.263.
10
COVID-19 Therapeutic Options Under Investigation.
Front Pharmacol. 2020 Aug 6;11:1196. doi: 10.3389/fphar.2020.01196. eCollection 2020.
本文引用的文献
1
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28.
2
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Neurology. 2013 Jul 9;81(2):174-81. doi: 10.1212/WNL.0b013e31829a3311. Epub 2013 May 22.
3
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.
4
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.
5
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
Neurology. 1983 Nov;33(11):1444-52. doi: 10.1212/wnl.33.11.1444.
Zotero 插件